Mar 2025 $1 M Private placement after listing Under $2 million 4
Cyclacel Pharmaceuticals, Inc.: Private sale, Mar 2025 × Investors in this round 4 investors had bought by the notice of Mar 25, 2025: 4 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Cyclacel Pharmaceuticals, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $1 M of $1 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Datuk Dr. Doris Wong Sing Ee · Executive Officer · The Chief Executive Officer Kiu Cu Seng · Executive Officer · The Chief Financial Officer Avraham Fock Ben-Tzvi · Director David Fock Natan · Director Kwang Fock Chong · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Company sold $1,000,000 of convertible Series E Preferred Stock”Signed by Datuk Dr.Doris Wong Sing Ee, Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 25, 2025. Read the notice at the SEC .
equity SEC Nov 2024 $2 M Private placement after listing $2 to $10 million 1
Cyclacel Pharmaceuticals, Inc.: Private sale, Nov 2024 × Investors in this round 1 investor had bought by the notice of Nov 26, 2024: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Cyclacel Pharmaceuticals, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $2 M of $2 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $189,969
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Paul McBarron · Executive Officer, Director Spiro Rombotis · Executive Officer, Director Brian Schwartz · Director Christopher Henney · Director Karin Walker · Director Kenneth Ferguson · Director Robert Spiegel · Director Samuel Barker · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round H.C. Wainwright & Co. (CRD 000000375) · New York, New York Sold in NY Remarks in the notice On fees: “The Company (a) paid Wainwright an aggregate cash fee of 7% of the gross proceeds, a management fee of 1% of the gross proceeds, expense reimbursement of $25,000 and (b) issued them warrants to purchase up to 298,137 shares.”Signed by Paul McBarron, Executive Vice President-Finance, CFO and COO. Source: SEC Form D, newest notice filed Nov 26, 2024. Read the notice at the SEC .
equity, options SEC May 2024 $8 M Private placement after listing $2 to $10 million 1
Cyclacel Pharmaceuticals, Inc.: Private sale, May 2024 × Investors in this round 1 investor had bought by the notice of May 17, 2024: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Cyclacel Pharmaceuticals, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $8 M of $8 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $640,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Paul McBarron · Executive Officer, Director Spiro Rombotis · Executive Officer, Director Brian Schwartz · Director Christopher Henney · Director Karin Walker · Director Kenneth Ferguson · Director Robert Spiegel · Director Samuel Barker · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round H.C. Wainwright & Co. (CRD 000000375) · New York, New York Sold in NY Remarks in the notice On fees: “In connection with the private placement, the placement agent received $640,000 in cash and warrants to purchase up to 298,137 shares of Common Stock exercisable at $2.0125 per share, among other items.”Signed by Paul McBarron, Executive Vice President-Finance, CFO and COO. Source: SEC Form D, newest notice filed May 17, 2024. Read the notice at the SEC .
equity, options SEC Dec 2020 $7 M Private placement after listing $2 to $10 million 1
Cyclacel Pharmaceuticals, Inc.: Private sale, Dec 2020 × Investors in this round 1 investor had bought by the notice of Jan 4, 2021: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Cyclacel Pharmaceuticals, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $7 M of $7 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Mark H. Kirschbaum · Executive Officer Paul McBarron · Executive Officer, Director Spiro Rombotis · Executive Officer, Director Brian L. Schwartz · Director Christopher S. Henney · Director Gregory T. Hradsky · Director Karin L. Walker · Director Lloyd T. Sems · Director Robert J. Speigel · Director Samuel L. Barker · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Paul McBarron, Executive Vice President-Finance, CFO and COO. Source: SEC Form D, newest notice filed Jan 4, 2021. Read the notice at the SEC .
equity, options SEC Mar 2012 $3 M Private placement after listing $2 to $10 million 7
Cyclacel Pharmaceuticals, Inc.: Private sale, Mar 2012 × Investors in this round 7 investors had bought by the notice of May 1, 2012: 7 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Cyclacel Pharmaceuticals, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $3 M of $3 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Judy Chiao · Executive Officer Paul McBarron · Executive Officer, Director Spiro Rombotis · Executive Officer, Director Christopher S. Henney · Director Daniel K. Spiegelman · Director David K. U'Prichard · Director Gregory K. Hradsky · Director John S. Banham · Director Lloyd K. Sems · Director Nicholas S. Bacopoulos · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Paul McBarron, CFO, COO and EVP-Finance. Source: SEC Form D, newest notice filed May 1, 2012. Read the notice at the SEC .
equity, options SEC Oct 2010 $15 M No. 1 $10 to $50 million 20
Cyclacel Pharmaceuticals, Inc.: Raise no. 1, Oct 2010 × Investors in this round 20 investors had bought by the notice of Oct 21, 2010: 20 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Cyclacel Pharmaceuticals, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $15 M of $22 M offered; $7 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $988,015
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Paul McBarron · Executive Officer, Director Spiro Rombotis · Executive Officer, Director Christopher Henney · Director Daniel K. Spiegelman · Director David K. U'Prichard · Director John Banham · Director Nicholas Bacopoulos · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Roth Capital Partners LLC (CRD 15407) · Newport Beach, California Sold in CA, NY Lazard Capital Markets LLC (CRD 134736) · New York, New York Sold in CA, NY Remarks in the notice On fees: “The Company has paid an aggregate of $988,014.67 in sales commissions. Up to an additional $451,741.14 will be paid, assuming all of the options are exercised in full.”Signed by Spiro Rombotis, President and CEO. Source: SEC Form D, newest notice filed Oct 21, 2010. Read the notice at the SEC .
equity, options SEC